デフォルト表紙
市場調査レポート
商品コード
1013735

表皮水疱症向けケア・治療の世界市場:将来予測 (2021年~2026年)

Epidermolysis Bullosa Care and Treatment market - Forecasts from 2021 to 2026

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 109 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
表皮水疱症向けケア・治療の世界市場:将来予測 (2021年~2026年)
出版日: 2021年04月07日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 109 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の表皮水疱症 (EB) 向けケア・治療の市場規模は、2019年には14億5376万1000米ドル、2026年には21億915万米ドルに達する見通しです。また、予測期間中に5.46%のCAGRで成長すると考えられています。現時点でEB向けの治療薬は上市されておらず、通常は疼痛管理や創傷ケア、栄養サポート、感染症予防、合併症の治療・予防といったケアが取られれています。一方、世界各国で大手製薬企業により、複数のEB治療薬の開発・治験が進行中です。

当レポートでは、世界の表皮水疱症向けケア・治療の市場について分析し、市場の基本構造や主な促進・抑制要因、全体的な市場規模の動向見通し、治療の種類別・地域別の詳細動向、競合情勢 (戦略展開状況、競争力の評価など)、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場の促進要因
  • 市場の抑制要因
  • ポーターのファイブフォース分析
  • 業界のバリューチェーンの分析

第5章 表皮水疱症向けケア・治療市場:治療の種類別の分析

  • イントロダクション
  • 表皮水疱症のケア
  • 薬物
  • 外科的治療
  • その他

第6章 表皮水疱症向けケア・治療市場:地域別の分析

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • その他
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • タイ
    • 台湾
    • インドネシア
    • その他

第7章 競合環境と分析

  • 主要企業・戦略の分析
  • 新興企業と市場の収益性
  • 企業合併・買収 (M&A)、契約、事業協力
  • ベンダー各社の競争力マトリックス

第8章 企業プロファイル

  • Amryt Pharma PLC
  • Abeona Therapeutics Inc.
  • Ember Therapeutics
  • TWi Pharmaceuticals Inc.
  • Amicus Therapeutics
  • InMed Pharmaceuticals Inc.
  • RegeneRx Biopharmaceuticals Inc.
  • Shionogi
  • Castle Creek Pharmaceuticals
  • Onconova Therapeutics
目次

The global Epidermolysis Bullosa care and treatment market is expected to grow at a compound annual growth rate of 5.46% over the forecast period to reach a market size of US2,109.150 million in 2026, from US$1,453.761 million in 2019. Epidermolysis Bullosa (EB) is known as a rare and infrequent medical condition that results in mucous membranes and easy blistering of the skin. The disease is due to the mutation of at least one in the sixteen different genes. There has not been a cure for this rare condition. Management usually involves pain control, wound care, nutritional support, controlling infections, and treatment or prevention of complications. Major companies have been developing novel and solutions for the treatment of this rare problem. Government funding and support, worldwide, have been imperative for the prevention and treatment of this rare medical condition. In December 2018, Fibrocell Science Inc, which has now been acquired by Castle Creek Pharmaceutical, had received US$900,000 from Epidermolysis Bullosa Research Foundation and EB Research Partnership to advance the company's FCX-007 gene therapy for the treatment of EB. Epidermolysis Bullosa is termed a genetic disease. There are three types of EB, known as EB simplex, Dystrophic EB, and Junctional EB.

Key Developments.

EB has been becoming one of the major medical conditions, worldwide. Around 500,000 people are being affected by EB, globally, according to several official sources. According to the data given by the National Epidermolysis Bullosa Registry, an estimated number of twenty newborns per one million live births in the United States has Epidermolysis Bullosa. There has not been an exact number of people with EB, but several estimates and official projections showed that around 25,000-50,000 people in the United States, have Epidermolysis Bullosa. Moreover, according to several official publications, the prevalence rate had increased in the past twenty years. These trends are expected to have a positive impact on the market, as the investment in the treatment of EB Is expected to surge in the coming years. In May 2021, Elon-gate, a cryptocurrency token for charitable giving, announced that it had donated US$150,000 to the EB research partnership (EBRP), the biggest worldwide non-profit funding research to discover and provide cures and treatments for EB. The EBRP funds research and development projects that study groundbreaking technologies, such as exon skipping, gene editing, and stem cell therapies, to cure EB by the year 2030. Other companies and institutions have also been making significant developments in the market. For instance, in April 2021, Onconova Therapeutics Inc., a biopharmaceutical firm focused on discovering and developing new and advanced products for patients with cancer, announced that their first and novel patients had been dosed in the company's Phase 2 study to learn and assess the safety and efficacy of rigosertib in patients with recessive dystrophic epidermolysis bullosa, advanced squamous cell carcinoma. The patient was dosed at EB House Austria, which has been a center for EB at the University Hospital Salzburg. This development is expected to have a positive impact on the market, during the forecast period. Various studies by the major and reputed institutions, private firms, and hospitals are having a substantial impact on the market. The development of novel, innovative and advanced solutions for the cure and treatment of EB is likely to surge in the coming years. With the COVID-19 pandemic affecting the global population, there has been a serious discussion to increase the investment in the treatment of rare genetic diseases. In October 2020, it was announced that a phase 2 trial of PTR-01, which has been a treatment for recessive dystrophic epidermolysis bullosa, had been dosed in its novel patient. The study had been taking place at Children's Hospital Colorado and Stanford University. These developments are expected to have a positive impact on the market, during the forecast period.

Competitive Analysis.

Major companies have been making significant developments in the market. The increase in the enrollment of patients for company's and medical institutions trials are likely to have a positive impact on the EB care and treatment market. For instance, in August 2019, RegeneRx Biopharmaceuticals Inc., a drug development company focused on tissue repair, protection, and regeneration, announced that their first and novel patient enrolled in phase 2 trial of epidermolysis bullosa had reacted positively to the company's novel and advanced drug candidate called as RGN-137. The trial had been sponsored by Lenus Therapeutics LLC, a joint venture owned by Yuang DNU Co. Ltd., and GtreeBNT, to develop RGN-137 in Canada, the USA, Japan, Korea, and Europe. The company has been making significant developments in the market, in the past few years. Other players are also making a substantial impact in the EB care and treatment market. For instance, in September 2020, InMed Pharmaceuticals, a clinical-stage pharmaceutical firm, had announced that all of their patients, that had participated in their second phase-1 trial to treat EB, with INM-755, had completed treatment. The company had been developing INM-755 to treat EB and other dermatological diseases. The firm's clinical trial had been a vehicle-controlled, double-blind, and randomized phase 1 study to examine and assess the tolerability and safety of INM-755 cream, that had been applied and rubbed on epidermal wounds in healthy volunteers. This development is expected to have a positive impact on the market, during the forecast period. The rise and growth in investment and funding in the treatment of EB has made a significant impact in the market. Castle Creek Pharmaceutical has been making substantial developments in the market. The company had acquired Fibrocell Science and has become a major player in the development of treatments and cures for epidermolysis bullosa. The company has also been developing FCX-007, an investigational gene therapy, for the treatment of recessive dystrophic epidermolysis bullosa. FCX-007, the company's novel solutions, had been a cell-based therapy that is used to genetically modify the patient's dermal fibroblasts. These developments are expected to have a positive impact on the market, during the forecast period.

Segmentation:

  • By Treatment Type
  • Epidermolysis Bullosa Care
  • Drugs
  • Surgical Treatment
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Taiwan
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Epidermolysis Bullosa Care and Treatment Market Analysis, By Treatment Type

  • 5.1. Introduction
  • 5.2. Epidermolysis Bullosa Care
  • 5.3. Drugs
  • 5.4. Surgical Treatment
  • 5.5. Others

6. Global Epidermolysis Bullosa Care and Treatment Market Analysis, by Ge-ography

  • 6.1. Introduction
  • 6.2. North America
    • 6.2.1. United States
    • 6.2.2. Canada
    • 6.2.3. Mexico
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
    • 6.3.3. Others
  • 6.4. Europe
    • 6.4.1. UK
    • 6.4.2. Germany
    • 6.4.3. France
    • 6.4.4. Italy
    • 6.4.5. Others
  • 6.5. The Middle East and Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. South Africa
    • 6.5.3. Others
  • 6.6. Asia Pacific
    • 6.6.1. Japan
    • 6.6.2. China
    • 6.6.3. India
    • 6.6.4. Thailand
    • 6.6.5. Taiwan
    • 6.6.6. Indonesia
    • 6.6.7. Others

7. Competitive Environment and Analysis

  • 7.1. Major Players and Strategy Analysis
  • 7.2. Emerging Players and Market Lucrativeness
  • 7.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 7.4. Vendor Competitiveness Matrix

8. Company Profiles

  • 8.1. Amryt Pharma PLC
  • 8.2. Abeona Therapeutics Inc.
  • 8.3. Ember Therapeutics
  • 8.4. TWi Pharmaceuticals Inc.
  • 8.5. Amicus Therapeutics
  • 8.6. InMed Pharmaceuticals Inc.
  • 8.7. RegeneRx Biopharmaceuticals Inc.
  • 8.8. Shionogi
  • 8.9. Castle Creek Pharmaceuticals
  • 8.10. Onconova Therapeutics